AGMB
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
AgomAb Therapeutics N.V. American Depositary Shares
- Nom
- AgomAb Therapeutics N.V. American Depositary Shares
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $439.7M
- Employés
- 62
- PDG
- Tim Knotnerus
- Site web
- https://agomab.com
- Marché
- ACRSALMSANABEQODTX
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 23000 titres (~197810 USD)
- Insiders
- Epstein David RKemula Pierre Thadee VictorKnotnerus Tim Jasper
- Total bought
-
$197,810
Avg buy (VWAP, 90d window) $8.69 vs last close $8.57 (-1.4%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-10-06
- Liquidity
- Thin $1,127,955/day · 20d vol
- Last synced
-
2026-10-26 21:10:05
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-21 | Epstein David R | Buy · P | 5,000 | $8.90 | $44,500 | Form 4 |
| 2026-10-08 | Epstein David R | Buy · P | 5,000 | $8.90 | $44,500 | Form 4 |
| 2026-10-06 | Epstein David R | Buy · P | 5,000 | $8.70 | $43,500 | Form 4 |
| 2026-10-06 | Kemula Pierre Thadee Victor | Buy · P | 2,000 | $8.54 | $17,080 | Form 4 |
| 2026-10-06 | Knotnerus Tim Jasper | Buy · P | 5,000 | $8.70 | $43,500 | Form 4 |
| 2026-10-05 | Epstein David R | Buy · P | 5,000 | $8.57 | $42,850 | Form 4 |
| 2026-10-05 | Knotnerus Tim Jasper | Buy · P | 6,000 | $8.48 | $50,880 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
AGMB presents a classic high-risk/high-reward binary setup: a strong insider cluster buy signal (75 catalyst score, 0.8 confidence) anchored by meaningful clinical milestones — positive STENOVA OLE data and first…
The first sentence of the analysis written for AGMB on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 6.52 · operating margin 0.0%
Suggested stop 7.55, nearest stored support minus 0.5 ATR(11.9% under the last close). Reward/risk to the next stored resistance is 1.27. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-13 Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn''s Disease Agomab announced that the first patient has been dosed in NOV-ERA, the Company''s Phase 2b study evaluating ontunisertib in patients with symptomatic FSCD.
- 2026-10-01 AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn''s Disease Transcript AgomAb Therapeutics NV (AGMB) Discusses Open-Label Extension Results of Phase IIa STENOVA Study in Fibrosing Crohn''s Disease Transcript
- 2026-10-01 Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn''s Disease Trial Agomab Therapeutics NV (NASDAQ:AGMB) reported results from the 48-week open-label extension portion of its Phase 2a STENOVA trial of ontunisertib for fibrostenotic Crohn''s disease.
- 2026-10-01 Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn''s Disease -- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn''s disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period -- -- Radiological assessment shows trend for fibrotic stricture stabilization over treatment course -- -- Sustained disease control observed across symptoms and disease activity scores in Open-Label Extension Study (OLE) -- -- Results support initiation of global NOV-ERA Phase 2b study in FSCD in the coming months -- -- Company to host webcast today at 8:30 a.m. Eastern Time -- Antwerp, Belgium, October 1, 2026 – Agomab Therapeutics NV (‘Agomab'') a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the 48-week OLE portion of the Phase 2a STENOVA trial evaluating ontunisertib in patients with FSCD, a severe manifestation of Crohn''s disease characterized by progressive bowel fibrosis and intestinal strictures.
- 2026-09-30 AgomAb Therapeutics NV (NASDAQ:AGMB) Stock Has Average Target Price of $37.50 AgomAb Therapeutics NV (NASDAQ: AGMB - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts
- 2026-09-16 AgomAb Therapeutics: Building A New Treatment Layer In Fibrosis Agomab Therapeutics targets fibrotic strictures in Crohn''s disease, aiming to create a new treatment category rather than compete with existing therapies. AGMB''s ontunisertib showed promising endoscopic results and safety in Phase 2a, with further validation needed in larger, controlled trials. Strong funding runway through 2029 and disciplined R&D execution support AGMB''s ability to advance clinical programs without immediate dilution risk.
- 2026-09-14 Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study -- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with AGMB-447 in IPF patients -- -- Clinical Trial Application (CTA) for INSPIRIA Phase 2 study in IPF patients submitted; Company intends to initiate study before year-end -- Antwerp, Belgium, September 14, 2026 – Agomab Therapeutics NV (‘Agomab''), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced positive results of the Phase 1 study of AGMB-447 in IPF patients. AGMB-447 is an investigational inhaled lung-restricted small molecule inhibitor of ALK5 (or TGFβR1) intended for the treatment of Idiopathic Pulmonary Fibrosis (IPF).1 The Phase 1 study of AGMB-447 is a three-part, double-blind, randomized, placebo-controlled single ascending dose (SAD; Part A; dose range: 1 mg QD (once daily) to 20 mg QD) and multiple ascending dose (MAD; Part B; dose range: 1 mg QD to 6 mg BID (twice daily)) study in healthy participants and multiple dose study in IPF patients (Part C; dose range: 4.5 mg BID to 6 mg BID).
- 2026-09-11 Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Agomab announced shareholders approved all resolutions submitted for consideration at the Company''s Special and Extraordinary General Shareholders'' Meeting
- 2026-09-03 Agomab to Participate in Upcoming Investor Conferences Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participate in the following upcoming investor conferences: Citi''s 2026 Biopharma Back to School Conference. Thursday, September 10, 2026 in New York, NY.
- 2026-08-25 This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 6.522 | 0.000 | 0.000 | 0.000 | |
| Quick Ratio | 6.522 | 0.000 | 0.000 | 0.000 | |
| Solvency Ratio | -2.733 | 0.000 | 0.000 | 0.000 | |
| Cash Ratio | 4.649 | 0.000 | 0.000 | 0.000 | |
| Price To Earnings Ratio | -9.741 | -11.228 | -42.754 | -62.189 | |
| Price To Earnings Growth Ratio | -6.137 | -0.037 | -1.045 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -6.137 | -0.037 | -1.045 | 0.000 | |
| Price To Earnings Diluted Ratio | -9.741 | -11.228 | -42.754 | -62.189 | |
| Price To Earnings Diluted Growth Ratio | -6.137 | -0.037 | -1.045 | 0.000 | |
| Price To Book Ratio | 4.642 | 0.000 | 0.000 | 0.000 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -11.744 | 0.000 | 0.000 | 0.000 | |
| Price To Operating Cash Flow Ratio | -11.745 | 0.000 | 0.000 | 0.000 | |
| Debt To Assets Ratio | 0.008 | 0.000 | 0.000 | 0.000 | |
| Debt To Equity Ratio | 0.010 | 0.000 | 0.000 | 0.000 | |
| Debt To Capital Ratio | 0.009 | 0.000 | 0.000 | 0.000 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.174 | 0.000 | 0.000 | 0.000 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -2.783 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | 0.000 | 0.000 | |
| Debt Service Coverage Ratio | -1,037.800 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | -987.917 | -716.731 | -1,006.129 | -502.978 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -41.261 | 0.000 | 0.000 | 0.000 | |
| Capital Expenditure Coverage Ratio | -12,935.250 | 0.000 | 0.000 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | -12,935.250 | 0.000 | 0.000 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -8.391 | 0.000 | 0.000 | 0.000 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 6.522 | ▲6.522 | ▲4.891 |
| Quick Ratio | 6.522 | ▲6.522 | ▲4.891 |
| Solvency Ratio | -2.733 | ▼-2.733 | ▼-2.050 |
| Cash Ratio | 4.649 | ▲4.649 | ▲3.487 |
| Price To Earnings Ratio | -9.741 | ▲1.487 | ▲21.737 |
| Price To Earnings Growth Ratio | -6.137 | ▼-6.100 | ▼-4.332 |
| Forward Price To Earnings Growth Ratio | -6.137 | ▼-6.100 | ▼-4.332 |
| Price To Earnings Diluted Ratio | -9.741 | ▲1.487 | ▲21.737 |
| Price To Earnings Diluted Growth Ratio | -6.137 | ▼-6.100 | ▼-4.332 |
| Price To Book Ratio | 4.642 | ▲4.642 | ▲3.482 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -11.744 | ▼-11.744 | ▼-8.808 |
| Price To Operating Cash Flow Ratio | -11.745 | ▼-11.745 | ▼-8.809 |
| Debt To Assets Ratio | 0.008 | ▲0.008 | ▲0.006 |
| Debt To Equity Ratio | 0.010 | ▲0.010 | ▲0.007 |
| Debt To Capital Ratio | 0.009 | ▲0.009 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.174 | ▲1.174 | ▲0.881 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -2.783 | ▼-2.783 | ▼-2.088 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▲1.000 | ▲0.750 |
| Debt Service Coverage Ratio | -1037.800 | ▼-1037.800 | ▼-778.350 |
| Interest Coverage Ratio | -987.917 | ▼-271.185 | ▼-184.478 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -41.261 | ▼-41.261 | ▼-30.946 |
| Capital Expenditure Coverage Ratio | -12935.250 | ▼-12935.250 | ▼-9701.438 |
| Dividend Paid And Capex Coverage Ratio | -12935.250 | ▼-12935.250 | ▼-9701.438 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -8.391 | ▼-8.391 | ▼-6.294 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $607.7M | $512.7M | $480.3M | $495.8M | |
| Enterprise value | $522.5M | $0 | $0 | $0 | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -10.10x | 0.00x | 0.00x | 0.00x | |
| EV / Free cash flow | -10.10x | 0.00x | 0.00x | 0.00x | |
| EV / EBITDA | -8.39x | 0.00x | 0.00x | 0.00x | |
| Net debt / EBITDA | 1.37x | 0.00x | 0.00x | 0.00x | |
| Current ratio | 6.52x | 0.00x | 0.00x | 0.00x | |
| Income quality | 0.83x | 0.00x | 0.00x | 0.00x | |
| Graham net-net | $2 | $0 | $0 | $0 | |
| Tax burden | 100.0% | 100.0% | 94.8% | 75.3% | |
| Interest burden | 100.1% | 100.1% | 100.3% | 100.4% | |
| Working capital | $102.6M | $0 | $0 | $0 | |
| Invested capital | $138.0M | $0 | $0 | $0 | |
| Return on assets | -40.7% | 0.0% | 0.0% | 0.0% | |
| Operating ROA | 0.0% | 0.0% | 0.0% | 0.0% | |
| Return on tangible assets | -52.1% | 0.0% | 0.0% | 0.0% | |
| Return on equity | -47.8% | 0.0% | 0.0% | 0.0% | |
| Return on invested capital | -43.8% | 0.0% | 0.0% | 0.0% | |
| Return on capital employed | -43.9% | 0.0% | 0.0% | 0.0% | |
| Earnings yield | -10.3% | -9.0% | -2.4% | -1.6% | |
| Free cash flow yield | -8.5% | 0.0% | 0.0% | 0.0% | |
| Capex / Op. cash flow | -0.0% | 0.0% | 0.0% | 0.0% | |
| Capex / Depreciation | 1.8% | 0.0% | 0.0% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 21.9% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years